Literature DB >> 15538222

Renal cell carcinoma MIB-1, Bax and Bcl-2 expression and prognosis.

Jukka P Kallio1, Pasi Hirvikoski, Heikki Helin, Tiina Luukkaala, Teuvo L J Tammela, Pirkko Kellokumpu-Lehtinen, Paula M Martikainen.   

Abstract

PURPOSE: Proliferation and programmed cell death (apoptosis) are key factors in oncogenesis and tumor progression. In carcinogenesis important regulators of apoptosis are members of the Bcl-2 family. In this family the Bcl-2 gene has an inhibitory effect on apoptosis, while Bax promotes cell death. In renal cell carcinoma (RCC) the associations between Bcl-2 proteins and RCC prognosis have been controversial. We evaluated Bax and Bcl-2 levels in RCC, and their associations with prognosis, proliferation and traditional prognostic factors.
MATERIALS AND METHODS: Our prospective study population comprised 138 consecutive patients who underwent radical nephrectomy for RCC. Immunostaining and semiquantitative indices for Ki-67 (MIB-1), Bax and Bcl-2 were estimated. Their associations with prognosis were explored.
RESULTS: On univariate analysis according to survival statistically significant differences were achieved by Bax (positive vs negative HR 3.04, 95% CI 1.27 to 7.23), Bcl-2 (positive vs negative HR 0.43, 95% CI 0.23 to 0.81), MIB-1 (continuous HR 1.03, 95% CI 1.001 to 1.064), Fuhrman nuclear class (4 vs 1 plus 2 HR 8.15, 95% CI 3.13 to 21.20) and stage (4 vs 1 HR 60.04, 95% CI 13.99 to 257.68). Only stage (HR 47.96, 95% CI 10.85 to 212.03) and Fuhrman classification (HR 4.32, 95% CI 1.60 to 11.65) attained statistical significance on Cox regression multivariate analysis.
CONCLUSIONS: In our prospective study Bax and Bcl-2 showed a statistically significant association with prognosis in RCC but did not achieve the status of independent prognostic factors. Further studies are needed to clarify the role of the apoptotic process in tumor progression and prognosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15538222     DOI: 10.1097/01.ju.0000144334.97639.bf

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

Review 1.  TRAIL-mediated signaling in prostate, bladder and renal cancer.

Authors:  Christina Voelkel-Johnson
Journal:  Nat Rev Urol       Date:  2011-06-14       Impact factor: 14.432

2.  The role of apoptosis repressor with a CARD domain (ARC) in the therapeutic resistance of renal cell carcinoma (RCC): the crucial role of ARC in the inhibition of extrinsic and intrinsic apoptotic signalling.

Authors:  Csaba Toth; Sarah Funke; Vanessa Nitsche; Anna Liverts; Viktoriya Zlachevska; Marcia Gasis; Constanze Wiek; Helmut Hanenberg; Csaba Mahotka; Peter Schirmacher; Sebastian Heikaus
Journal:  Cell Commun Signal       Date:  2017-05-02       Impact factor: 5.712

3.  The tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a group of medulloblastomas and supratentorial primitive neuroectodermal tumours: an association of CA IX with poor prognosis.

Authors:  Kristiina Nordfors; Joonas Haapasalo; Miikka Korja; Anssi Niemelä; Jukka Laine; Anna-Kaisa Parkkila; Silvia Pastorekova; Jaromir Pastorek; Abdul Waheed; William S Sly; Seppo Parkkila; Hannu Haapasalo
Journal:  BMC Cancer       Date:  2010-04-18       Impact factor: 4.430

4.  Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1.

Authors:  Henry Zall; Arnim Weber; Robert Besch; Niko Zantl; Georg Häcker
Journal:  Mol Cancer       Date:  2010-06-24       Impact factor: 27.401

5.  Nucleostemin mRNA is expressed in both normal and malignant renal tissues.

Authors:  Y Fan; Z Liu; S Zhao; F Lou; S Nilsson; P Ekman; D Xu; X Fang
Journal:  Br J Cancer       Date:  2006-06-05       Impact factor: 7.640

6.  Harnessing the p53-PUMA axis to overcome DNA damage resistance in renal cell carcinoma.

Authors:  Xiaoguang Zhou; Yanis Tolstov; Aysenur Arslan; Wilfried Roth; Carsten Grüllich; Sascha Pahernik; Markus Hohenfellner; Stefan Duensing
Journal:  Neoplasia       Date:  2014-12       Impact factor: 5.715

7.  Uncoupling of PUMA Expression and Apoptosis Contributes to Functional Heterogeneity in Renal Cell Carcinoma - Prognostic and Translational Implications.

Authors:  Xiaoguang Zhou; Jielin Li; Christina Marx; Yanis Tolstov; Geraldine Rauch; Esther Herpel; Stephan Macher-Goeppinger; Wilfried Roth; Carsten Grüllich; Sascha Pahernik; Markus Hohenfellner; Stefan Duensing
Journal:  Transl Oncol       Date:  2015-12       Impact factor: 4.243

8.  MicroRNA-34a: A Key Regulator in the Hallmarks of Renal Cell Carcinoma.

Authors:  Eman A Toraih; Afaf T Ibrahiem; Manal S Fawzy; Mohammad H Hussein; Saeed Awad M Al-Qahtani; Aly A M Shaalan
Journal:  Oxid Med Cell Longev       Date:  2017-09-20       Impact factor: 6.543

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.